Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers

Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers

IntroductionTransformation from lung adenocarcinoma (LUAD) to small cell lung cancer (SCLC) is one of the mechanisms responsible for acquired EGFR-TKIs resistance. Although it rarely happens this event determines a rapid disease deterioration and needs specific treatment.Patient and methodWe report...

Full description

Bibliographic Details
Main Authors:	Jun Li, Bing Wei, Junnan Feng, Xinxin Wu, Yuxi Chang, Yi Wang, Xiuli Yang, Haiyan Zhang, Sile Han, Cuiyun Zhang, Jiawen Zheng, Harry J. M. Groen, Anke van den Berg, Jie Ma, Hongle Li, Yongjun Guo
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Series:	Frontiers in Endocrinology
Subjects:	small cell lung cancer transformation lung adenocarcinoma osimertinib TP53 and RB1 loss MYC amplification
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2022.1006480/full

Similar Items

Profiling of driver mutations in lung adenocarcinoma patients identifies rare compound EGFR mutations sensitive to second-generation EGFR-TKIs
by: Jun Li, et al.
Published: (2024-12-01)

Corrigendum: Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients
by: Jun Li, et al.
Published: (2022-01-01)

Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients
by: Jun Li, et al.
Published: (2021-05-01)

Characterization of Synonymous BRCA1:c.132C>T as a Pathogenic Variant
by: Jun Li, et al.
Published: (2022-01-01)

Application of Third-generation TKIs in EGFR-mutated Non-small Cell Lung Cancer
by: XU Wenwen, et al.
Published: (2021-12-01)

Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with EGFR exon 20 insertion mutations
by: Chao Shi, et al.
Published: (2022-09-01)

Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan
by: Jerry Shu-Hung Kuo, et al.
Published: (2025-01-01)

Pathogenic germline variants in BRCA1 and TP53 increase lung cancer risk in Chinese
by: Bing Wei, et al.
Published: (2023-12-01)

Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real‐world clinical example
by: Bing Wei, et al.
Published: (2019-05-01)

Regulation of dendritic cell maturation in osimertinib-treated lung adenocarcinoma patients
by: Ming-Fang Wu, et al.
Published: (2023-09-01)

Identification of a Rare EGFR T790I Mutation in Lung Adenocarcinoma Sensitive to Osimertinib
by: Yu Wang, et al.
Published: (2021-10-01)

Successful osimertinib retreatment after extremely early onset severe pneumonitis in first‐line treatment of lung adenocarcinoma
by: June Hong Ahn
Published: (2020-09-01)

Analysis of adverse drug reactions of Osimertinib in the 2nd‐line treatment of EGFR mutant advanced nonsmall cell lung cancer
by: Yingying Jiang, et al.
Published: (2022-06-01)

STK11 genetic alterations in metastatic EGFR mutant lung cancer
by: Dandan Yin, et al.
Published: (2025-02-01)

Lung Adenocarcinoma Harboring EGFR Kinase Domain Duplication (EGFR-KDD) Confers Sensitivity to Osimertinib and Nivolumab: A Case Report
by: Jie Li, et al.
Published: (2020-12-01)

Machine Learning-Based CT Radiomics Analysis for Prognostic Prediction in Metastatic Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation Receiving Third-Generation EGFR-TKI Osimertinib Treatment
by: Xin Tang, et al.
Published: (2021-09-01)

Centipeda minima active components and mechanisms in lung cancer
by: Cuiyun Gao, et al.
Published: (2023-03-01)

Multiple synchronous primary lung adenocarcinomas with distinct epidermal growth factor receptor mutations: A case report
by: Matthew Siskin, et al.
Published: (2022-09-01)

Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung Cancer: A Retrospective Study
by: Mu Y, et al.
Published: (2019-10-01)

Effect of the First-Line Therapy with Osimertinib for a Metastatic Choroidal Tumor in Advanced-Stage Lung Cancer: A Case Report
by: Ikuko Umeda, et al.
Published: (2023-07-01)

A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer
by: Chul Kim, et al.
Published: (2021-09-01)

Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis
by: Xiao-Fang Yi, et al.
Published: (2022-06-01)

Paravertebral dexmedetomidine as an adjuvant to ropivacaine protects against independent lung injury during one-lung ventilation: a preliminary randomized clinical trial
by: Wei Zhang, et al.
Published: (2018-06-01)

A “triple whammy” in adenocarcinoma lung
by: Mahismita Patro, et al.
Published: (2019-01-01)

Successful Chemotherapy for Diffuse Cystic Lung Metastases during Targeted Therapy with Osimertinib in a Patient with Non-Small-Cell Lung Cancer: A Literature Review and a Rare Case Report
by: Akira Matsukida, et al.
Published: (2023-11-01)

Cardiac events and dynamic echocardiographic and electrocardiogram changes following osimertinib treatment in lung cancer
by: Jonathan N. Le, et al.
Published: (2024-12-01)

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer
by: Yufeng Li, et al.
Published: (2023-04-01)

Enhancing intracranial efficacy prediction of osimertinib in non-small cell lung cancer: a novel approach through brain MRI radiomics
by: Xin Tang, et al.
Published: (2024-08-01)

EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma
by: Chan Xiang, PhD, et al.
Published: (2021-07-01)

Abnormal activation of NF‐κB and MAPK signaling pathways affect osimertinib resistance and influence the recruitment of myeloid‐derived suppressor cells to shape the immunosuppressive tumor immune microenvironment
by: Chao Wang, et al.
Published: (2023-07-01)

Targeting Transient Receptor Potential Melastatin‐2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung Cancer
by: Zhen Chen, et al.
Published: (2024-09-01)

Osimertinib Re-challenge for EGFR-mutant NSCLC after  Osimertinib-induced Interstitial Lung Disease: A Case Report
by: Junjie GU, et al.
Published: (2021-11-01)

Case report: The effect of induction targeted therapies in stage III driver mutants non-small cell lung cancer
by: Waleed Kian, et al.
Published: (2024-11-01)

SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness
by: Leiming Xia, et al.
Published: (2021-07-01)

Image-guided percutaneous ablation for lung malignancies
by: Youlan Shang, et al.
Published: (2022-11-01)

Pretreatment Neutrophil-to-Lymphocyte Ratio and Smoking History as Prognostic Factors in Advanced Non–Small Cell Lung Cancer Patients Treated with Osimertinib
by: Ji Young Park, et al.
Published: (2022-04-01)

Modern vector in treatment of patients with lung cancer: tyrosine kinase inhibitors in epidermal growth factor receptor mutations (literature review)
by: O.M. Smorodska, et al.
Published: (2021-06-01)

Relationship of EGFR-TKI Targeted Therapy and Pyroptosis in Non-small Cell Lung Cancer
by: CHEN Jiachen, et al.
Published: (2023-12-01)

The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study
by: Yu Feng, et al.
Published: (2022-09-01)

Olaparib Combined With Dacomitinib in Osimertinib-Resistant Brain and Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Report and Systematic Review
by: Hui Zhang, et al.
Published: (2022-04-01)